Unicycive Therapeutics Inc
NASDAQ:UNCY 10:53:10 AM EDT
Products
Unicycive Enters Into Licensing Agreement With Lotus For Renazorb In Korea
Published: 02/02/2023 14:43 GMT
Unicycive Therapeutics Inc (UNCY) - Unicycive Announces Exclusive License and Development Agreement With Lotus for Renazorb in Republic of Korea.
Unicycive Therapeutics Inc - Agreement Includes Upfront Payment, Royalties, and Milestone Payments.
Unicycive Therapeutics Inc - Lotus Will Be Responsible for Development, Registration Filing and Approval of Renazorb in Republic of Korea.
Unicycive Therapeutics - Under Terms of Deal Lotus Will Be Responsible for Development, Registration Filing, Approval of Renazorb in Republic of Korea.
Unicycive Therapeutics Inc - Lotus Will Have Sole Responsibility for Importation of Drug Product From Unicycive.
Unicycive Therapeutics Inc - Lotus Will Have Sole Responsibility for Costs of Commercialization of Renazorb in Republic of Korea.
Unicycive Therapeutics Inc - Co Will Receive an Upfront Payment of $750,000 and May Receive Up to $4.45 Million in Milestone Payments and Tiered Royalties.
Unicycive Therapeutics Inc - Agreement Includes Upfront Payment, Royalties, and Milestone Payments.
Unicycive Therapeutics Inc - Lotus Will Be Responsible for Development, Registration Filing and Approval of Renazorb in Republic of Korea.
Unicycive Therapeutics - Under Terms of Deal Lotus Will Be Responsible for Development, Registration Filing, Approval of Renazorb in Republic of Korea.
Unicycive Therapeutics Inc - Lotus Will Have Sole Responsibility for Importation of Drug Product From Unicycive.
Unicycive Therapeutics Inc - Lotus Will Have Sole Responsibility for Costs of Commercialization of Renazorb in Republic of Korea.
Unicycive Therapeutics Inc - Co Will Receive an Upfront Payment of $750,000 and May Receive Up to $4.45 Million in Milestone Payments and Tiered Royalties.